Best Peptides for Sleep

What are the best peptides for sleep, ranked by evidence?

The peptide with the most direct human sleep data is DSIP, followed by indirect GH-axis peptides like CJC-1295, then epithalon, which has the weakest human support.

"Best" here means best studied and most transparently reported, not most effective. Sleep peptide research is thin, and most of it is old, small, or done in animals. The ranking below reflects how much human evidence exists and how strong it is, not a promise of results.

Does DSIP actually improve sleep in humans?

Early human research reported that DSIP improved sleep in people with poor sleep, and described it as sleep-promoting rather than sedating (Schneider-Helmert, PubMed 6895513).

DSIP was first described as a factor that could shift sleep patterns without knocking a person out the way a classic sedative does. In the clinical report by Schneider-Helmert (PubMed 6895513), poor sleepers were studied and some measures of sleep improved. The effect sizes were modest, and the sample context was small by modern standards.

The honest problem: even after many years of study, reviewers have described DSIP as an unresolved riddle, meaning its true mechanism and reliability are not settled (PMID 16539679). So DSIP has the most direct human sleep signal of any peptide here, and that signal is still weak and inconsistent. This page reports what the literature says. It does not tell you to use it.

Can GHRH peptides like CJC-1295 help sleep through growth hormone?

The connection is indirect: CJC-1295 is a GHRH analog shown to raise growth hormone and IGF-1 (Teichman et al., 2006), and GH secretion in the body overlaps with slow-wave (deep) sleep.

The logic researchers describe is a loop. Deep sleep is when much natural GH is released, and GHRH signaling drives GH. So a GHRH analog that sustains GH and IGF-1, as CJC-1295 did in Teichman et al., 2006, is proposed to interact with that same system. Related secretagogues like ipamorelin were characterized as selective GH releasers (Raun et al., 1998).

Two cautions matter. First, raising GH is not the same as a validated sleep outcome; the sleep benefit here is extrapolated, not demonstrated in a sleep-endpoint trial cited in this brief. Second, GH-axis manipulation carries metabolic considerations: a related oral secretagogue, MK-677, raised fasting glucose and lowered insulin sensitivity in one trial (Nass et al., 2008). That is a reminder that "boosts GH" is not automatically benign.

What about epithalon for circadian rhythm and sleep?

Epithalon is marketed around pineal gland and circadian effects, but strong, completed human sleep trials are not available to support those claims, so treat it as unverified.

The interest in epithalon comes from ideas about the pineal gland and melatonin-related timing. That is a plausible-sounding target for sleep, because the pineal gland is part of circadian control. The gap is evidence: this brief does not carry a high-quality human trial showing epithalon improves measured sleep, and this page will not invent one. If you see confident sleep claims for epithalon elsewhere, ask what completed human data supports them.

How strong is the safety evidence for sleep peptides?

Long-term safety of these peptides used for sleep is not established, and none of them is a proven or approved sleep treatment.

Most of the human data is small, old, or focused on other endpoints. Mechanisms like GH-axis stimulation have known metabolic trade-offs (Nass et al., 2008). DSIP's own mechanism remains unresolved (PMID 16539679). "Research suggests" is the honest ceiling here, not "safe for daily long-term use." Personal decisions about anything in this class belong with a qualified clinician who can weigh your full picture.